Big Pharma is looking for innovative ways to realise value from non-core assets—including discovery technologies. The UK's Proteome Sciences is the latest European biotech to benefit, as Aventis clears out its house.
For more than a decade, start-ups have sought to convince drug companies to sell them the drugs and drug candidates...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?